Host defence mechanisms against dengue virus infection of mice.
Serum obtained from mice 3 to 5 weeks after the third i.p. dose of dengue type 2 virus (DV) protected recipient mice against intracerebral challenge with DV, whereas the serum obtained after 1 and 2 weeks provided minimum protection. Adoptive intravenous transfer of immune spleen cells obtained from mice 1 to 5 weeks after immunization did not protect recipient mice against even a small dose (10 LD50) of DV. Depletion of T-cells by treatment of mice with anti-thymocyte serum did not potentiate DV infection. Development of a cell-mediated immune response (CMI) against DV was noted only at two periods by the leucocyte migration inhibition test (LMI), with borderline values of 20 and 21%. Dengue virus did not cause illness or death in mice when given by i.p. or i.v. routes and this was not affected by pre-treatment of mice with silica to damage local macrophages. It is concluded that humoral antibody plays a critical role in recovery from primary dengue virus infection of mice whereas CMI and macrophages appear to have no protective role.
D000818:Animals; D000914:Antibodies, Viral / Q000096:biosynthesis; D000961:Antilymphocyte Serum / Q000009:adverse effects; D003520:Cyclophosphamide / Q000009:adverse effects; D003715:Dengue / Q000276:immunology* / Q000628:therapy; D003716:Dengue Virus / Q000276:immunology; D004195:Disease Models, Animal; D007111:Immunity, Cellular; D007167:Immunotherapy; D008264:Macrophages / Q000276:immunology; D008297:Male; D051379:Mice; D012822:Silicon Dioxide / Q000009:adverse effects; D013601:T-Lymphocytes / Q000276:immunology
D000914:Antibodies, Viral; D000961:Antilymphocyte Serum; D012822:Silicon Dioxide; D003520:Cyclophosphamide